NEWS RELEASE: Cardiomatics cooperates with the BIOTRONIK sales organisation in Germany to accelerate the growth of its leading AI-powered ECG analysis solution in the German market
- BIOTRONIK Sales Organisation in Germany will distribute Cardiomatics’ AI-powered ECG analysis solution in combination with its net_ECG advanced ECG-Patch Holter Monitor.
- The partnership will drive the adoption of AI in early detection and management for individuals who may be at risk of a cardiac event.
Cardiomatics, a pioneer in AI-powered ECG analysis solutions, and the BIOTRONIK sales organisation for Germany, a leading medical technology company in the field of cardiac rhythm management, have agreed upon a sales cooperation. This cooperation aims to accelerate the adoption of artificial intelligence in the early detection and management of individuals susceptible to cardiac events.
As part of the cooperation, BIOTRONIK will distribute Cardiomatics’ AI-powered ECG analysis solution alongside its net_ECG advanced ECG-Patch Holter Monitor in Germany. This combined offering will provide healthcare professionals with enhanced capabilities for precise cardiac monitoring and analysis.
“BIOTRONIK is one of the leading companies in the cardiac rhythm management devices market. Their commitment to saving lives and improving patients’ quality of life is very well aligned with Cardiomatics aims to make cardiac diagnostics more accurate, fast, and easy. We believe that our AI-based ECG analysis software will create great synergies with the BIOTRONIK ECG-Patch product portfolio and will nicely fit into the journey of cardiac patients.” – says Rafał Samborski, CEO of Cardiomatics.
The significance of this cooperation is underlined by the alarming statistics surrounding cardiovascular disease, the leading cause of global mortality. With approximately 17.9 million annual deaths attributed to cardiovascular complications, the imperative for improved early detection and management is clear. Studies suggest that up to 80% of premature heart attacks and strokes could be prevented with timely intervention.
”I am excited about the potential of AI to help early detection of cardiac rhythm abnormalities. The partnership between Cardiomatics and Biotronik is a promising step towards integrating this cutting-edge technology with patient care to improve outcomes for those at risk of cardiac events” – says Prof. Dr. David Duncker, Head of Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
Cardiomatics has been at the forefront of developing AI solutions to enhance diagnostic cardiology since 2018, to make diagnostic cardiology more insightful, productive, and enjoyable. The Cardiomatics platform has analyzed over 250 thousand long-term ECG signals and garnered the distinction of being the first in its category to receive EU-MDR certification in October 2023.
“By combining Cardiomatics´ cutting-edge AI-powered ECG analysis solution with our net_ECG advanced ECG-Patch Holter Monitor, we aim to revolutionize the early detection and management of cardiac events. This collaboration supports our commitment to providing innovative solutions that enhance patient care and outcomes in cardiovascular health”, says Oliver Rehermann, Director of Marketing, e-Health & Connected Cardiac Care, BIOTRONIK Germany
About Cardiomatics
Cardiomatics is a cloud-based platform employing medical-grade AI algorithms for automatic ECG analysis. The solution enables accurate, fast, and easy-to-use ECG analysis for medical professionals across primary and secondary care, including cardiac clinics, service providers and hospitals. Since its establishment in 2017, Cardiomatics has analysed over 7 million hours of ECG signals for commercial purposes. This tool is used across 15+ countries, including Germany, France, Switzerland, and Poland. Cardiomatics has also been used in clinical studies with Cornell University (USA), the University of Basel (Switzerland), and other leading academic centres. cardiomatics.com
About Biotronik
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries. biotronik.com
The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
